Patents by Inventor James Robert Henry

James Robert Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20100076001
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2007
    Publication date: March 25, 2010
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Melissa Kate Slater, Yan Wang
  • Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
    Patent number: 7666879
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong
  • IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS
    Publication number: 20090227622
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 10, 2009
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander Mclean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Yip, Boyu Zhong
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20090105229
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 23, 2009
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel
  • Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
    Publication number: 20080207685
    Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Application
    Filed: November 16, 2004
    Publication date: August 28, 2008
    Applicant: Eli Lilly And Company
    Inventors: James Robert Henry, Yihong Li, Jeffrey Michael Scheryantz, Alan M. Warshawsky
  • Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
    Patent number: 7405305
    Abstract: The present invention provides kinase inhibitors of Formula (I)
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Jochen Ammenn, Timothy Paul Burkholder, Joshua Ryan Clayton, Scott Eugene Conner, Brian Eugene Cunningham, Thomas Albert Engler, Kelly Wayne Furness, James Robert Henry, Sushant Malhotra, Mark Joseph Tebbe, Guoxin Zhu, YiHong Li, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR)
    Publication number: 20080167310
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Application
    Filed: October 3, 2007
    Publication date: July 10, 2008
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky, Maria Rosario Gonzalez-Garcia
  • Modulators of peroxisome proliferator activated receptors (PPAR)
    Patent number: 7282501
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: October 16, 2007
    Assignee: Eli Lilly and Company
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky
  • Urea linker derivatives for use as PPAR modulators
    Patent number: 6984661
    Abstract: The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl substituted C1-C8 alkyl, aryl-C0-4-alkyl, substituted aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, substituted heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and substituted C3-C6 cycloalkylaryl-C0-2-alkyl; (b) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH2)n COOR19 and substituted (CH2)n COOR19.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: January 10, 2006
    Assignee: Eli Lilly and Company
    Inventors: James Robert Henry, YiHong Li